AbbVie Inc. (ABBV) FY2026 Q2 P&L / Income Statement

AbbVie Inc. (ABBV) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

16,990,000,000 US dollars

Cost of products sold

4,291,000,000 US dollars

Gross profit (calculated)

12,699,000,000 US dollars

Operating expenses (calculated)

6,267,000,000 US dollars

Operating earnings

6,432,000,000 US dollars

Other income (expense), net (calculated)

negative 2,154,000,000 US dollars

Earnings before income tax expense

4,278,000,000 US dollars

Income tax expense

662,000,000 US dollars

Net earnings

3,616,000,000 US dollars

Aesthetics - Botox Cosmetic

728,000,000 US dollars

Aesthetics - Juvederm Collection

245,000,000 US dollars

Aesthetics - Other Aesthetics

309,000,000 US dollars

Immunology - Humira

756,000,000 US dollars

Immunology - Rinvoq

2,525,000,000 US dollars

Immunology - Skyrizi

5,505,000,000 US dollars

Neuroscience - Botox Therapeutic

1,042,000,000 US dollars

Neuroscience - Other Neuroscience

117,000,000 US dollars

Neuroscience - Qulipta

350,000,000 US dollars

Neuroscience - Ubrelvy

392,000,000 US dollars

Neuroscience - Vraylar

1,071,000,000 US dollars

Neuroscience - Vyalev

256,000,000 US dollars

Oncology - Elahere

211,000,000 US dollars

Oncology - Epkinly

103,000,000 US dollars

Oncology - Imbruvica

532,000,000 US dollars

Oncology - Venclexta

771,000,000 US dollars

Other Key Products - Linzess

295,000,000 US dollars

Other Key Products - Mavyret

295,000,000 US dollars

Undisclosed (calculated)

1,487,000,000 US dollars

Selling, general and administrative

3,632,000,000 US dollars

Research and development

2,344,000,000 US dollars

Acquired IPR&D and milestones

291,000,000 US dollars

Other operating income

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $3.61 B; to noncontrolling interests: $3.00 M.